Alps Advisors Inc. raised its stake in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 9.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,330 shares of the biotechnology company’s stock after buying an additional 2,364 shares during the quarter. Alps Advisors Inc. owned about 0.10% of Five Prime Therapeutics worth $1,159,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. State Street Corp boosted its position in shares of Five Prime Therapeutics by 25.7% during the 1st quarter. State Street Corp now owns 1,249,520 shares of the biotechnology company’s stock valued at $45,175,000 after acquiring an additional 255,488 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Five Prime Therapeutics by 162.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 298,395 shares of the biotechnology company’s stock valued at $8,984,000 after acquiring an additional 184,888 shares during the last quarter. Pictet Asset Management Ltd. boosted its position in shares of Five Prime Therapeutics by 51.4% during the 3rd quarter. Pictet Asset Management Ltd. now owns 468,088 shares of the biotechnology company’s stock valued at $19,150,000 after acquiring an additional 158,863 shares during the last quarter. Artal Group S.A. bought a new position in shares of Five Prime Therapeutics during the 2nd quarter valued at approximately $4,517,000. Finally, Victory Capital Management Inc. boosted its position in shares of Five Prime Therapeutics by 28.9% during the 2nd quarter. Victory Capital Management Inc. now owns 666,440 shares of the biotechnology company’s stock valued at $20,066,000 after acquiring an additional 149,340 shares during the last quarter. 83.86% of the stock is owned by institutional investors and hedge funds.

Shares of Five Prime Therapeutics, Inc. (FPRX) opened at $25.96 on Tuesday. Five Prime Therapeutics, Inc. has a 52-week low of $21.41 and a 52-week high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.19). The firm had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.72) EPS. equities research analysts predict that Five Prime Therapeutics, Inc. will post -5.56 EPS for the current year.

A number of research analysts have recently commented on FPRX shares. Royal Bank Of Canada increased their target price on Five Prime Therapeutics from $41.00 to $50.00 and gave the company an “outperform” rating in a research report on Monday, November 6th. BMO Capital Markets upgraded Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday, October 16th. BidaskClub downgraded Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $52.00 target price (down from $55.00) on shares of Five Prime Therapeutics in a research report on Thursday, August 10th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $64.00.

In other Five Prime Therapeutics news, Director William R. Ringo sold 2,000 shares of Five Prime Therapeutics stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $38.00, for a total value of $76,000.00. Following the transaction, the director now owns 2,000 shares in the company, valued at $76,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the transaction, the director now owns 1,200 shares in the company, valued at approximately $48,312. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,400 shares of company stock worth $175,666. Insiders own 6.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/14/five-prime-therapeutics-inc-fprx-shares-bought-by-alps-advisors-inc.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.